[1] Antar SA, Ashour NA, Sharaky M, et al. Diabetes mellitus: classification, mediators, and complications; a gate to identify potential targets for the development of new effective treatments[J]. Biomed Pharmacother, 2023, 168: 115734. doi: 10.1016/j.biopha.2023.115734. [2] Dilworth L, Facey A, Omoruyi F. Diabetes mellitus and its metabolic complications: the role of adipose tissues[J]. Int J Mol Sci, 2021, 22: 7644. doi: 10.3390/ijms22147644. [3] Tam CS, Xie W, Johnson WD, et al. Defining insulin resistance from hyperinsulinemic-euglycemic clamps[J]. Diabetes Care, 2012, 35: 1605-1610. [4] Babin V, Taran F, Audisio D. Late-stage carbon-14 labeling and isotope exchange: emerging opportunities and future challenges[J]. JACS Au, 2022, 2: 1234-1251. [5] Pan F, Liu X, Wan J, et al. Advances and prospects in deuterium metabolic imaging (DMI): a systematic review of in vivo studies[J]. Eur Radiol Exp, 2024, 8: 65. doi:10.1186/s41747-024-00464-y. [6] Zhao X, An X, Yang C, et al. The crucial role and mechanism of insulin resistance in metabolic disease[J]. Front Endocrinol (Lausanne), 2023, 14: 1149239. doi: 10.3389/fendo.2023.1149239. [7] Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance[J]. Physiol Rev, 2018, 98: 2133-2223. [8] Kim JK. Hyperinsulinemic-euglycemic clamp to assess insulin sensitivity in vivo[J]. Methods Mol Biol, 2009, 560: 221-238. [9] Faubert B, Tasdogan A, Morrison SJ, et al. Stable isotope tracing to assess tumor metabolism in vivo[J]. Nat Protoc, 2021, 16: 5123-5145. [10] Robert JJ, Koziet J, Chauvet D, et al. Use of 13C-labeled glucose for estimating glucose oxidation: some design considerations[J]. J Appl Physiol (1985), 1987, 6: 1725-1732. [11] Petersen MC, Vatner DF, Shulman GI. Regulation of hepatic glucose metabolism in health and disease[J]. Nat Rev Endocrinol, 2017, 13: 572-587. |